Veracyte was founded in 2008 and is headquartered in South San Francisco, US

Co-Founder & CEO

CFO

Chief Medical Officer

Chief Scientific Officer

Chief Commercial Officer

VP, Laboratory Operations & Medical Director

Veracyte has offices in South San Francisco and Austin

South San Francisco, US (HQ)

300 6000 Shoreline Ct

Austin, US

100 12357 Riata Trace Pkwy

Veracyte's revenue was reported to be $16.4 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 16.4 m |

## Gross profit (Q1, 2017) | 10.1 m |

## Gross profit margin (Q1, 2017), % | 62% |

## Net income (Q1, 2017) | (8.2 m) |

## EBIT (Q1, 2017) | (7.5 m) |

## Market capitalization (22-Aug-2017) | 264.9 m |

## Cash (31-Dec-2016) | 59.2 m |

## EV | 230.6 m |

Veracyte's current market capitalization is $264.9 m.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 21.9 m | 38.2 m | 49.5 m | 65.1 m |

## Revenue growth, % | 75% | 30% | 31% | |

## Cost of goods sold | 12.6 m | 16.6 m | 21.5 m | 25.5 m |

## Gross profit | 9.3 m | 21.6 m | 28 m | 39.6 m |

## Gross profit Margin, % | 42% | 57% | 57% | 61% |

## EBIT | (23.2 m) | (29 m) | (33.5 m) | (28.8 m) |

## EBIT margin, % | (106%) | (76%) | (68%) | (44%) |

## Net Income | (25.6 m) | (29.4 m) | (33.7 m) | (31.4 m) |

USD | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|

## Revenue | 11.2 m | 11.9 m | 12.3 m | 13.6 m | 14.7 m | 18.6 m | 16.4 m |

## Cost of goods sold | 4.6 m | 5.1 m | 5.6 m | 6.3 m | 6.3 m | 6.4 m | 6.3 m |

## Gross profit | 6.7 m | 6.8 m | 6.7 m | 7.3 m | 8.4 m | 12.2 m | 10.1 m |

## Gross profit Margin, % | 59% | 57% | 54% | 54% | 57% | 66% | 62% |

## R&D expense | 2.8 m | 3.1 m | 3.6 m | 3.5 m | 4.3 m | 4 m | 4 m |

## General and administrative expense | 5.8 m | 5.5 m | 5.7 m | 6.2 m | 6.1 m | 5.8 m | 6 m |

## Operating expense total | 8.6 m | 8.6 m | 9.3 m | 9.7 m | 10.3 m | 9.8 m | 10 m |

## EBIT | (7.6 m) | (9.1 m) | (8.9 m) | (9.8 m) | (10.5 m) | (4.9 m) | (7.5 m) |

## EBIT margin, % | (67%) | (76%) | (72%) | (72%) | (72%) | (26%) | (46%) |

## Interest expense | 89 k | 90 k | 92 k | 367 k | 785 k | 799 k | 800 k |

## Net Income | (7.6 m) | (9.1 m) | (8.9 m) | (10.1 m) | (11.2 m) | (5.6 m) | (8.2 m) |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 71.2 m | 35 m | 39.1 m | 59.2 m |

## Accounts Receivable | 1.1 m | 3.1 m | 3.5 m | 8.8 m |

## Inventories | 1.5 m | 1.2 m | 1.5 m | 2.1 m |

## Current Assets | 76.4 m | 43.3 m | 47.9 m | 73.6 m |

## PP&E | 3 m | 4.2 m | 10.3 m | 11.5 m |

## Goodwill | 1.1 m | 1.1 m | 1.1 m | |

## Total Assets | 79.6 m | 64.8 m | 75.3 m | 101 m |

## Accounts Payable | 5.3 m | 7.4 m | 5.1 m | 2.4 m |

## Total Debt | 4.9 m | 4.9 m | 5 m | 24.9 m |

## Current Liabilities | 15.4 m | 17.1 m | 14.7 m | 11.5 m |

## Total Liabilities | 41.5 m | |||

## Additional Paid-in Capital | 142.1 m | 156.4 m | 200 m | 239.6 m |

## Retained Earnings | (85.6 m) | (115 m) | (148.7 m) | (180.1 m) |

## Total Equity | 56.4 m | 41.4 m | 51.3 m | 59.6 m |

## Debt to Equity Ratio | 0.1 x | 0.1 x | 0.1 x | 0.4 x |

## Debt to Assets Ratio | 0.1 x | 0.1 x | 0.1 x | 0.2 x |

## Financial Leverage | 1.4 x | 1.6 x | 1.5 x | 1.7 x |

USD | Q1, 2015^{} | Q2, 2015^{} |
---|---|---|

## Cash | 25.8 m | 51 m |

## Current Assets | 33.7 m | 60.7 m |

## PP&E | 4.1 m | 4.2 m |

## Goodwill | 1.1 m | 1.1 m |

## Total Assets | 55.1 m | 82.5 m |

## Accounts Payable | 6.9 m | 2.7 m |

## Current Liabilities | 14.1 m | 11.8 m |

## Additional Paid-in Capital | 157.7 m | 196.8 m |

## Retained Earnings | (122.6 m) | (131.8 m) |

## Total Equity | 35.1 m | 65.1 m |

## Financial Leverage | 1.6 x | 1.3 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (25.6 m) | (29.4 m) | (33.7 m) | (31.4 m) |

## Depreciation and Amortization | 999 k | 1.2 m | 2.3 m | 3.5 m |

## Accounts Receivable | (683 k) | (2 m) | (558 k) | (5.3 m) |

## Accounts Payable | 3.3 m | 1.9 m | (3.5 m) | (1.4 m) |

## Cash From Operating Activities | (19.2 m) | (27.6 m) | (27 m) | (28 m) |

## Purchases of PP&E | (1.3 m) | (2 m) | (6.2 m) | (4.2 m) |

## Cash From Investing Activities | (1.3 m) | (9 m) | (6.7 m) | (4.2 m) |

## Cash From Financing Activities | 77.7 m | 436 k | 37.7 m | 52.3 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (7.6 m) | (9.1 m) | (8.9 m) | (10.1 m) | (11.2 m) | (5.6 m) | (8.2 m) | ||

## Accounts Receivable | 3.4 m | 6.3 m | 9.1 m | ||||||

## Accounts Payable | 8.5 m | 8.6 m | 6.9 m | 2.7 m | 6.6 m | 4.3 m | 2.7 m | 3.1 m | 2.6 m |

USD | Y, 2017 |
---|---|

## EV/EBIT | -30.7 x |

## Revenue/Employee | 76.1 k |